Humana Inc.

Humana Inc. Earnings Recaps

HUM Health Care 3 recaps
Q1 2026 Apr 30, 2026

Humana shares closed up 2.9% following first quarter results described by management as in line with expectations. The company reiterated its commitment to restoring Medicare Advantage margins and highlighted steady progress toward 2028 goals, but did not materially surprise on guidance or outlook.

Key takeaways
  • Management confirmed results for Q1 were "where we expect it to be," with membership growth and retention described as on track three months into the year.
  • Humana remains focused on restoring a sustainable margin of at least 3% by 2028, expecting meaningful progress toward that target in 2027.
  • The company cited continued margin pressures from medical cost trends outpacing program funding and reiterated the need for benefit adjustments.
  • Medicaid membership increased by approximately 50,000, mainly from new contracts in Michigan, Illinois, and South Carolina.
  • Leadership transition in the Insurance segment announced, with Aaron Martin set to lead Medicare Advantage operations and eventually succeed segment President George Renaudin.
Full recap
Q3 2025 Nov 5, 2025

Humana delivered a solid performance in Q3 2025, maintaining its full-year EPS outlook of approximately $17 while executing effectively amid evolving market conditions.

Key takeaways
  • Medical cost trends are in line with expectations, supporting ongoing profitability.
  • Medicare new sales are trending at the high end of anticipated ranges, with improved channel mix contributing to enhanced customer lifetime value.
  • The company is focused on reducing voluntary attrition through stable benefit strategies and enhanced customer service, showing favorable early indicators in the AEP.
  • Stars performance shows operational gains, with significant year-over-year improvements expected in key metrics for bonus year '28.
Full recap
Q2 2025 Aug 1, 2025

Humana reported a strong second quarter, exceeding expectations primarily due to improved individual Medicare Advantage membership and robust performance from CenterWell Pharmacy, leading to an upward revision of its full-year EPS guidance.

Key takeaways
  • Increased full-year EPS outlook raised from approximately $16.25 to $17.
  • Individual Medicare Advantage membership decline was less than anticipated, aided by retention of previously lost members.
  • New initiatives announced to simplify the prior authorization process and enhance member experience through a partnership with Epic for integrated health plan information.
  • Significant progress towards targeted Stars ratings for '27/'28, currently navigating a re-filed legal case regarding Stars litigation.
  • Ongoing transformation initiatives aimed at optimizing operations, including an early retirement program to streamline costs.
Full recap